Lombard Odier Asset Management Europe Ltd Reduces Stock Holdings in Bruker Corporation $BRKR

Lombard Odier Asset Management Europe Ltd reduced its position in shares of Bruker Corporation (NASDAQ:BRKR) by 51.4% in the 1st quarter, Holdings Channel.com reports. The firm owned 66,216 shares of the medical research company’s stock after selling 70,008 shares during the quarter. Lombard Odier Asset Management Europe Ltd’s holdings in Bruker were worth $2,392,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Gabelli Funds LLC grew its stake in shares of Bruker by 16.0% in the 1st quarter. Gabelli Funds LLC now owns 14,500 shares of the medical research company’s stock valued at $524,000 after buying an additional 2,000 shares during the period. Public Employees Retirement System of Ohio raised its position in shares of Bruker by 38.7% during the 1st quarter. Public Employees Retirement System of Ohio now owns 107,067 shares of the medical research company’s stock valued at $3,867,000 after buying an additional 29,892 shares during the period. Sei Investments Co. raised its position in shares of Bruker by 19.8% during the 1st quarter. Sei Investments Co. now owns 258,901 shares of the medical research company’s stock valued at $9,351,000 after buying an additional 42,781 shares during the period. Walleye Capital LLC lifted its holdings in Bruker by 6,405.1% in the first quarter. Walleye Capital LLC now owns 14,116 shares of the medical research company’s stock valued at $510,000 after acquiring an additional 13,899 shares during the last quarter. Finally, Cetera Investment Advisers lifted its holdings in Bruker by 4.9% in the first quarter. Cetera Investment Advisers now owns 13,184 shares of the medical research company’s stock valued at $476,000 after acquiring an additional 612 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on BRKR shares. Leerink Partners raised their target price on Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Barclays upped their price target on Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Guggenheim raised their price objective on Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Finally, Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Bruker has a consensus rating of “Hold” and a consensus price target of $56.79.

Bruker Stock Performance

Shares of Bruker stock opened at $60.45 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The stock has a market capitalization of $9.20 billion, a price-to-earnings ratio of -251.88, a price-to-earnings-growth ratio of 1.94 and a beta of 1.29. The business has a 50-day moving average of $56.32 and a 200 day moving average of $46.32. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $64.54.

Bruker (NASDAQ:BRKR) last released its earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The company had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date was Monday, June 22nd. Bruker’s payout ratio is -83.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.